Target intelligence / Profile preview

Reticulon-4 receptor-like 1 (RTN4RL1)

Target: RTN4RL1
Molecular classification: Receptor, Cell surface protein, GPI-anchored protein (predicted post-translational modification)

Overview

Reticulon-4 receptor-like 1 (RTN4RL1) is a cell surface receptor predominantly expressed in the nervous system, where it plays a functionally redundant role in postnatal brain development, axon regeneration, and formation of the corpus callosum. It restricts axon outgrowth and regeneration by interacting with extracellular chondroitin sulfate proteoglycans and signaling via Rho activation, influencing the actin cytoskeleton. RTN4RL1 protects motoneurons from apoptosis and is also implicated in the regulation of dendritic spine and synapse number during brain development. Diseases associated with RTN4RL1 include Miller-Dieker lissencephaly syndrome and microcephaly. While no current drugs specifically target RTN4RL1, agents affecting the Rho/ROCK pathway, which is downstream of Nogo receptor signaling (NgR1-3), are in clinical trials for CNS injury

Other names: Nogo receptor-like 2Nogo-66 receptor homolog 2Nogo-66 receptor-related protein 3NgR3NGRH2DKFZp547J144

Mechanism of action

Inhibition of Rho kinase (ROCK) to promote axon regeneration in injury models (downstream of Nogo receptor signaling)

Biological functions

Negative regulation of axon regenerationRegulation of axon migration across the brain midlineFormation of the corpus callosumProtection against motoneuron apoptosisRestriction of neurite outgrowthInhibition of dendritic spine and synapse formation during developmentActivation of Rho signaling, leading to actin cytoskeleton reorganization

Disease associations

Neurodegenerative disease (role in CNS axon regeneration)Miller-Dieker lissencephaly syndromeMicrocephalyPotential relevance in nervous system trauma (e.g., spinal cord injury)

Safety considerations

Possible concerns with modulating axon growth or synaptic connectivity in the CNS (potential for neuropsychiatric or developmental effects)Specific therapeutic safety data lacking due to no direct drugs in clinical use

Interacting drugs

No drugs directly targeting RTN4RL1 are currently approved, but Rho kinase (ROCK) inhibitors (such as Cethrin) target downstream pathways related to NgR signaling (mostly described for NgR1/RTN4R, but relevant to RTN4RL1)

Biomarkers

None established for patient selection or efficacy monitoring

Beyond the preview

Go deeper on Reticulon-4 receptor-like 1 (RTN4RL1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reticulon-4 receptor-like 1 (RTN4RL1).

Explore the full profile